Legal & General Group Plc Acquires 2,065 Shares of Medpace Holdings, Inc. $MEDP

Legal & General Group Plc lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.9% during the 4th quarter, Holdings Channel reports. The firm owned 44,082 shares of the company’s stock after purchasing an additional 2,065 shares during the period. Legal & General Group Plc’s holdings in Medpace were worth $24,759,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Cibc World Market Inc. bought a new position in Medpace in the third quarter valued at approximately $5,033,000. Capital Fund Management S.A. increased its stake in Medpace by 129.5% in the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock valued at $16,665,000 after acquiring an additional 18,287 shares during the last quarter. Dorsey Wright & Associates bought a new position in Medpace in the third quarter valued at approximately $5,082,000. Victory Capital Management Inc. increased its stake in Medpace by 32.9% in the third quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock valued at $15,702,000 after acquiring an additional 7,565 shares during the last quarter. Finally, Intech Investment Management LLC increased its stake in Medpace by 31.9% in the third quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock valued at $9,458,000 after acquiring an additional 4,448 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Mizuho set a $582.00 price objective on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. BMO Capital Markets cut their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Robert W. Baird cut their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Finally, Leerink Partners cut their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $447.11 on Monday. The firm has a market cap of $12.77 billion, a PE ratio of 28.10, a price-to-earnings-growth ratio of 2.27 and a beta of 1.18. The firm’s fifty day moving average is $457.47 and its 200-day moving average is $513.36. Medpace Holdings, Inc. has a 52 week low of $291.28 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by insiders.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.